- Home
- VIRX
as 07-26-2024 4:00pm EST
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CARDIFF |
| Market Cap: | 25.5M | IPO Year: | N/A |
| Target Price: | $7.20 | AVG Volume (30 days): | 112.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $1.68 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Viracta Therapeutics Inc. (VIRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | VIRX | CFO and COO | Feb 25 '24 | Sell | $0.73 | 3,405 | $2,493.14 | 102,306 | SEC Form 4 |
| Rothera Mark | VIRX | President and CEO | Nov 30 '23 | Buy | $0.49 | 52,094 | $25,734.44 | 52,094 | SEC Form 4 |
| Rothera Mark | VIRX | President and CEO | Nov 30 '23 | Buy | $0.49 | 47,906 | $23,627.24 | 100,000 | SEC Form 4 |
Latest Viracta Therapeutics Inc. News
VIRX Breaking Stock News: Dive into VIRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Viracta Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
2 months ago
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
GlobeNewswire
3 months ago
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
3 months ago
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
GlobeNewswire
4 months ago
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
GlobeNewswire
5 months ago
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
5 months ago
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Compare VIRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIRX Viracta Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.